REGN Furnishes earnings results
Summary
Regeneron Pharmaceuticals, Inc. expects to include an acquired in-process research and development (IPR&D) charge of approximately $102 million on a pre-tax basis for the first quarter 2026. This charge is anticipated to negatively impact both GAAP and non-GAAP net income per diluted share by approximately $0.81. The charge primarily stems from premiums on equity securities purchased, development milestone, and up-front payments related to collaboration and licensing agreements. These are preliminary estimates and subject to finalization.
Why It Matters
The expected pre-tax IPR&D charge of approximately $102 million, translating to an approximate $0.81 negative impact on diluted EPS for Q1 2026, is a material signal. Investors should note this as it directly reduces the company's profitability for the quarter.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how REGN traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View REGN Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“per diluted share for the first quarter 2026 by approximately $0.81.”
— From Item 2.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000872589
- Filing Date
- Wednesday, April 8, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive